ClinicalTrials.gg
RecruitingNCT07489209Updated May 20, 2026

A Dose-exploration Study of EDP167 in HoFH

A Phase 2 interventional study of EDP167 in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by Eddingpharm (Zhuhai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Eddingpharm (Zhuhai) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.

Planned enrollment
6th of 11
20 · median 20
Started
2026
with 1 other
Phase 2
5 of 12
3 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Eddingpharm (Zhuhai) Co., Ltd.

Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 11th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.

Read the detailed description

Angiopoietin-like 3 protein (ANGPTL3) is a key regulator of lipid metabolism. Clinical studies have shown that inhibition of ANGPTL3 could exert lipid-lowering effects in patients with dyslipidemia. EDP167 is a novel N-Acetylgalactosamine (GalNAc)-conjugated siRNA therapeutic that selectively silences hepatic ANGPTL3 mRNA expression, offering a promising strategy for lipid lowering. This trial includes two phase, main study phase (including screening period and 24 weeks treatment period) and extension phase (including 6 months treatment period). In main study phase, patients with HoFH will be randomized into two dose cohorts (200mg and 300mg, 10 subjects each), receiving EDP167 injections on Day 1 and at Week 12. At Week 24 of the main study phase, subjects will be evaluated and enter the extension phase, receiving EDP167 injections at Month 0 and at Month 3. The follow-up will last till Month 6 in extension phase to evaluate the efficacy, safety, PK profile and PD effects (ANGPTL3, low-density lipoprotein cholesterol [LDL-C], triglyceride [TG], and other lipid parameters) in HoFH patients after multiple EDP167 injections.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia (HoFH)

Keywords

  • Dyslipidemia
  • ANGPTL3
  • siRNA
  • HoFH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old, male or female, and weight ≥40 kg.
  2. Genetic diagnosis or clinical diagnosis of HoFH.
  3. Fasting serum LDL-C ≥2.6 mmol/L.
  4. Follow a daily low-fat diet during the study.
  5. Receiving stable and tolerable lipid-lowering treatment or other drugs for chronic diseases treatments for certain periods before the study, and maintain the stable treatments throughout the study.
  6. Women of (WOCBP) must have a negative serum pregnancy test at screening and a negative pregnancy test prior to receiving EDP167 at baseline.
  7. Agree to use measures that comply with regulations and the protocol requirements during the study, and until 6 months after the last dose.
  8. Understand the study procedures, voluntarily participate, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to the drug in this study, its components or similar drugs.
  2. Used any antisense oligonucleotide (ASO) or small interfering nucleic acid (siRNA) drugs within 12 months prior to randomization.
  3. Received treatment targeting ANGPTL3 or Apolipoprotein C3 (ApoC3), or have participated in other clinical trials within 6 months or 5 half-life (whichever longer) prior to screening.
  4. Received health supplements or other medications that have been used for lipid-lowering purposes within 4 weeks prior to screening.
  5. Received Lipoprotein apheresis within 8 weeks prior to screening.
  6. A weight change of >10% within 4 weeks prior to randomization, or planning to undergo weight-loss surgery or weight intervention treatment during the study period.
  7. Starting a new diet plan or having significant differences from the previous diet within 4 weeks prior to randomization.
  8. Presence of diseases that would affect lipid or lipoprotein levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, hypothyroidism or hyperthyroidism, etc., which are poorly controlled, and in the opinion of the Investigator will interfere with the accurate assessment of the study results.
  9. Had (NYHA) grade III-IV heart failure within 12 months prior to randomization, or acute coronary syndrome or stroke within 6 months prior to randomization.
  10. Performed coronary intervention within 6 months prior to randomization, or plan to perform coronary intervention during the study.
  11. Have a history of major surgery within 3 months prior to screening, or plan to undergo major surgery during the study.
  12. History of , unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years prior to the first dose of EDP167; excluding adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, or incidental histological findings of prostate cancer (TNM stage T1a or T1b).
  13. Clinical evidence of active infections or other major or poorly controlled serious diseases, any other conditions that in the opinion of the Investigator may interfere with the study results or put the subjects at excessive risk.
  14. Have a history of current existence of alcohol or drug abuse per evaluation of the investigator.
  15. Uncontrolled hypertension at screening (blood pressure >160/100 mmHg).
  16. Subjects with any of the following laboratory abnormalities at screening: a) fasting serum TG≥5.6 mmol/L; b) Glycosylated (HbA1c)>8.5%; c) (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transpeptidase (GGT)>1.5× (Upper Limit Of Normal), total (TBIL)>2×ULN; d) (PT) or activated partial thromboplastin time (APTT) or International Normalized Ratio (INR) abnormal; e) surface antigen (HBsAg) or antibody to virus (HCVAb) or (HIV) positive; f) estimated (eGFR)\<30 mL/min/1.73m2.
  17. Donated or lost blood ≥400 mL within 3 months prior to screening.
  18. Women who are pregnant, breastfeeding or planning for pregnancy.
  19. Other conditions that the Investigator would consider the subject is not suitable to participate in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    EDP167-200mg

    EDP167 200mg (N=10)

    Drug: EDP167

  • Experimental
    EDP167-300mg

    EDP167 300mg (N=10)

    Drug: EDP167

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at week 24 of the main study phase.

    Time frame: Up to week 24 of the main study phase

Secondary outcomes

  1. To evaluate the change from baseline in serum LDL-C level.

    Time frame: Up to month 6 of the extension phase

  2. To evaluate the change from baseline in serum angiopioetin-like protein 3 (ANGPTL3) level.

    Time frame: Up to month 6 of the extension phase

  3. To evaluate the change from baseline in serum triglyceride (TG) level.

    Time frame: Up to month 6 in the extension phase

  4. To evaluate the change from baseline in serum total cholesterol (TC) level.

    Time frame: Up to month 6 in the extension phase

  5. To evaluate the change from baseline in serum non-high-density lipoprotein cholesterol (non-HDL-C) level.

    Time frame: Up to month 6 in the extension phase

  6. To evaluate the change from baseline in serum high-density lipoprotein cholesterol (HDL-C) level.

    Time frame: Up to month 6 in the extension phase

  7. To evaluate the change from baseline in serum lipoprotein (a) [Lp (a)] level.

    Time frame: Up to month 6 in the extension phase

  8. To evaluate the change from baseline in serum Apolipoprotein B (ApoB) level.

    Time frame: Up to month 6 in the extension phase

  9. The proportion of subjects with serum LDL-C level <2.6mmol/L at week 24.

    Time frame: Up to week 24 of the main study phase

  10. The proportion of subjects with serum LDL-C level decreased by ≥50% compared with the baseline at week 24.

    Time frame: Up to week 24 of the main study phase

  11. The serum concentration of EDP167 over time.

    Time frame: Up to month 6 of the extension phase

  12. To evaluate the safety and tolerability of EDP167 in subjects with HoFH.

    Number of participants with adverse events and serious adverse events, with clinically significant changes in vital signs, in electrocardiogram readings, in physical examination, and in laboratory tests.

    Time frame: Up to month 6 of the extension phase

  13. To evaluate the immunogenicity of EDP167.

    The incidence and titer of antibodies against EDP167.

    Time frame: Up to month 6 of the extension phase

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Oct 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 24, 2026
StartActual
Feb 6, 2026
Primary completionEst.
Oct 4, 2026
CompletionEst.
Mar 31, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07489209
Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Feb 6, 2026
Primary completion
Oct 4, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Wei Song
Contact
Sophie.Song@eddingpharm.com
86-13817957624
Kefei Dou, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP167

Start the discussion